AP337A

AP337A - Salts of substituted quinoline compounds and their use as inhibitors of gastric acid secretion.

Info

Publication number: AP337A
Application number: APAP/P/1992/000352A
Authority: AP
Inventors: Robert John Ife; Colin Andrew Leach
Original assignee: Smithkline Beecham Intercredit B V
Priority date: 1991-01-29
Filing date: 1992-01-27
Publication date: 1994-04-08
Also published as: HU9302201D0; NO932722D0; FI933376A; HUT67609A; MX9200338A; JPH06504541A; CZ153293A3; AU652028B2; NZ241408A; CN1064268A; MA22401A1; FI933376A0; SK70993A3; NO932722L; IL100791A0; PT100056A; IE920267A1; CA2099117A1; AU1179992A; WO1992012969A1

Abstract

Salts of substituted quinoline compounds and their use as inhibitors of gastric acid secretion

Description

The present invention relates to certain salts of a quinoline compound, pharmaceutical compositions containing them and their use in therapy as inhibitors of gastric acid secretion.

Quinoline compounds which have activity as gastric acid secretion inhibitors are known in the art, for example, EP-330485-A discloses a series of 4-amino-3acylquinoline derivatives in which the quinoline is substituted in the 8-position by, for example, hydroxyalkyl and hydroxyalkoxy groups.

The compounds of EP 330485-A have been found to have poor dissolution rates in water and, as a consequence, could potentially exhibit poor bioavailability in vivo and hence low and poorly reproducible levels of therapeutic activity. It has now been found that the problem of poor dissolution can be overcome by producing the compounds in the form of a particular class of salts. Furthermore, in selecting compounds for use in therapy it is important to take a number or criteria into account, for example, in addition to physical qualities such as good dissolution (and hence good bioavailability), the desired level of intrinsic potency and duration of action of the chosen compounds has to be at the desired level. It has been found that a particular compound of EP-330485-A when produced in the form of a salt as described herein, in addition to having the desired physical qualities such as a high dissolution rate, also has the desired levels of potency and duration of action and, as such, form the subject matter of the present invention.

-2The present invention therefore provides in a first aspect a compound of structure (I):

in the form of a salt characterised in that the salt is that formed by reaction of said compound of structure (I) with a strong acid.

As used herein, the term strong acid shall be taken to mean an acid with a pka of less than about 4.0. The nature of such acids vill be apparent to those skilled in the art and include, for example, mineral acids such as hydrochloric acid, and sulphonic acids such as alkyl sulphonic acids, in particular methane sulphonic acid.

Particularly preferred salts of the present invention are those formed by reaction with hydrochloric acid or methane sulphonic acid, that is to say,

3-butyryl-4-(2-methylphenylamino)-8-(2-hydroxyethoxy)quinoline hydrochloride, and 3-butyryl-4-(2-methylphenylamino) -8-(2-hydroxyethoxy)quinoline mesylate.

The salts of the present invention, in particular the hydrochloride and mesylate salts referred to above, have been found to exhibit exceptionally fast intrinsic dissolution rates when compared to the free base compound of structure (I) disclosed in EP-330485-A. Thus,

AP 0 0 0 3 3 7

3whereas the free base has a poor dissolution rate and, as such, may be expected in vivo to exhibit poorly reproducible bioavailability (and so be less effective therapeutically), the salts of the present invention are expected to exhibit a much more consistent bioavailability (since their dissolution rates are far more favourable) and to prove more effective per given dose and more reliably effective per given dose on administration to patients.

The salts described herein can be used in therapy in the treatment of gastrointestinal diseases in mammals, in particular humans. Such diseases include, for example, gastric and duodenal ulcers, aspiration pneumonitis and Zollinger-Ellison syndrome. Further, the salts can be used in the treatment of other disorders where an anti-secretory effect is desirable, for example in patients with a history of chronic and excessive alcohol consumption, and in patients with gastrooesophageal reflux disease (GERD).

In therapeutic use, the salts can be administered in a standard pharmaceutical composition comprising the salt and a pharmaceutically acceptable carrier. The present invention provides in a further aspect therefore a pharmaceutical composition comprising a salt as described herein in association with a pharmaceutically acceptable carrier.

Suitable pharmaceutical compositions are as described in EP-330485-A.

Suitable daily dosage regimens for an adult patient may be, for example, an oral dose of between 1 and 1000 mg, preferably between 1 and 500 mg, or an

-4intravenous, subcutaneous or intramuscular dose of between 0.1 and 100 mg, preferably between 0.1 and 25 mg of the salts described herein, the salt being administered in a unit dosage 1 to 4 times a day.

In addition, the salts can be co-administered with further active ingredients such as antacids (for example, magnesium carbonate or hydroxide and aluminium hydroxide), non-steroidal anti-inflammatory drugs, steroids or nitrite scavengers or other drugs used for treating gastric ulcers (for example, prostanoids or H₂-antagonists such as cimetidine).

AP Ο Ο Ο 3 3 7

-5EXAMPLE 1

3-Butyryl-4-(2-methylphenylamino)-8-(2-hydroxyethoxy)quinoline can be prepared according to the procedures described in EP-330485-A.

Preparation of 3-butvrvl-4-(2-methvlphenvlamino)-8-(2hydroxyethoxy)quinoline hydrochloride

3-Butyryl-4-(2-methylphenylamino)-8-(2-hydroxyethoxy ) quinoline (10 g) was suspended in methanol (100 ml) at room temperature, cone, hydrochloric acid added slowly to give a clear solution, then the solvent evaporated.

The residue was twice taken up in 2-propanol and re-evaporated, and was then recrystallised from

2-propanol/ether to obtain the desired salt (9.7 g), m.p. 214-215°C.

^C22^H24^N2°3·^Η01* ⁰ * ^2H2°

Found C 65.50, H 6.21, N 6.88

Requires C 65.32, H 6.33, N 6.93.

EXAMPLE 2

Preparation of 3-butvrvl-4-(2-methvlphenvlamino)-8-(225 hvdroxvethoxv)quinoline mesylate

3-Butyryl-4-(2-methylphenylamino)-8-(2-hydroxyethoxy) quinoline (60 g) was suspended in ethyl acetate (400 ml), warmed to 50°C, and methanesulphonic acid (16.3 g) added with vigorous stirring. The desired salt crystallised on cooling, and was filtered off and washed

	with ethyl	acetate;	yield 50.1	g, m.p. 83-85°C
	^C22^H24^N2°3	.ch₄o₃s.h₂	0
	Found	C 57.78,	H 6.28, N	5.84
35	Requires	C 57.73,	H 6.32, N	5.85.

... i.

I

-Λ#»·

-610

Claims

Claims in the form of a salt, characterised in that the salt is that formed by reaction of the compound of structure (I)

15 with a strong acid.
2. A salt according to claim 1 which is 3-butyryl-4- (2-methylphenylaraino) -8-(2-hydroxyethoxy) quinoline hydrochloride.
3. A salt according to claim 1 which is 3-butyryl-
4-(2-methylphenylamino)-8-(2-hydroxyethoxy)quinoline mesylate.

25 4. A process for preparing a salt according to claim 1 which comprises reacting a compound of structure (I) as described in claim 1 with a strong acid.
5. A pharmaceutical composition comprising a salt according to claim 1 in association with a pharmaceutically acceptable carrier.

AP Ο Ο Ο 3 3 7

-76. A pharmaceutical composition comprising 3-butyryl-4-(2-methylphenylamino)-8-(2-hydroxyethoxy)quinoline hydrochloride in association with a pharmaceutically acceptable carrier.
7. A salt according to claim 1 for use in therapy.
8. 3-Butyry1-4-(2-methylphenylamino)-8-(2-hydroxy ethoxy)quinoline hydrochloride for use in therapy.